Assessing pricing models for innovative medicines, access to healthcare and performance of primary care

The Expert Panel on effective ways of investing in health is preparing three opinions on priority topics of the EU health strategy: payment models for high-cost medicines, access to healthcare and the performance of primary care. The opinions will be ready in the second semester of 2017 and will feed into the further policy work of the Commission.

In the EU, the pharmaceutical legislation lays down harmonised regulatory standards and tools for the authorisation and supervision of medicines. However, efforts to invest on development and timely authorisation of innovative medicines face challenges, such as the sustainability of health systems, patient access and affordability.

In April 2017 the European Commission published a recommendation establishing the European Pillar of Social Rights. The recommendation includes a principle on access to good quality preventive and curative health care.

 

Strong primary care can contribute to consolidating the overall health system’s performance by providing affordable and accessible care, guiding patients through the health system to find the most appropriate care (substantially reducing avoidable hospital admissions), focusing on individual needs and offering tailored, patient-centred care.

For more information on the assessment of pricing models for innovative medicines, access to healthcare and performance of primary care from ec.europa.eu.